Sanofi to increase competition in atopic dermatitis market after Dupixent success
Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Sanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade)
Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...
The Pharma Letter7h
AstraZeneca's Fasenra set to revolutionize COPD treatment
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
MM&M23h
Skyrizi claims year-end TV ad crown among Rx, OTC pharma brands
Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.
Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript)
Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ETCompany ParticipantsPaul Hudson - Chief Executive OfficerFrancois-Xavier Roger ...
FiercePharma10d
Verona touts 'exceptionally strong' launch of blockbuster hopeful COPD treatment Ohtuvayre
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...
The Pharma Letter1d
Sanofi to increase competition in atopic dermatitis market after Dupixent’s success
French pharma major Sanofi's participation at the JP Morgan Healthcare Conference was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future.